Heart Failure Highlights: New HFpEF recommendations released as cases keep rising | Risks tied to NSAID use

HFpEF now accounts for a majority of heart failure cases, highlighting the importance of ensuring both primary care providers and dedicated heart teams know as much about this topic as possible. 

The device, described as the "world's smallest heart pump," has received the FDA's breakthrough device designation for two indications. 

The link between NSAIDs such as ibuprofen and heart failure was especially strong among patients 80 years old and older. For patients 65 years old and younger, on the other hand, no such link was identified. 

Certain uses of the CentriMag acute circulatory support system were previously limited to six hours, but the FDA has now cleared long-term treatment so that clinicians have more time to provide high-quality care. 

The company has seen significant improvements in revenue and the number of centers actively using its technology.

Teams from three universities have received four-year research grants to examine the relationship between chronic stress and CVD. Each team plans to study the issue from a different angle.

A new laser imaging technology may be able to determine which donor hearts are viable for transplant and which will result in poor outcomes, without the need for coronary angiography or use of contrast agents that can damage an explanted heart.